Could a pill make radiation work better for sarcoma patients?
NCT ID NCT05938374
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested whether adding the drug fluzoparib to standard preoperative radiation therapy improves outcomes for people with soft tissue sarcoma in the arms, legs, or trunk. Fifty-two adults took part, receiving either radiation alone or radiation plus fluzoparib before surgery. The study looked at wound complications, side effects, and quality of life after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fluzoparib (a PARP inhibitor drug taken orally)
What this could lead to
If successful, this could lead to a new treatment option that improves tumor control and reduces wound complications after surgery for soft tissue sarcoma.
What could go wrong
This is a small, early-phase trial with only 52 participants, so results may not apply broadly. Adding fluzoparib to radiation may increase side effects like fatigue or bone marrow suppression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Jishuitan Hospital
Beijing, Beijing Municipality, China
-
Cancer Hospital and Institute, National Cancer Center, Chinese Academy of Medical Sciences & Peking Union Medical Center
Beijing, Beijing Municipality, China